Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489-322 lisdexamfetamine augmentation study in adults with major depressive disorder
2011-003018-17Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Lisdexamfetamine augmentation with Placebo augmentation (2 arms). Started Aug 2012; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-003018-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003018-17.